26 - 27 November, 2019 | Millennium Gloucester Hotel London Kensington, London, United Kingdom

Day One

8:00 - 8:45 Registration and Welcome Coffee

8:45 - 9:00 Welcome Speech and Chairman's Opening Remarks

Martyn Fish, Partner at HGF Limited

Martyn Fish

Partner
HGF Limited

9:00 - 9:30 Lord Neuberger's Observations on the Doctrine of Equivalents

·         Exploring the recent challenges of proportionality to the Doctrine of Equivalents
·         How will the UK interpret patents in the future?
·         Lord Neuberger’s experts opinion on key matters in Hong Kong and Singapore
Lord Neuberger, Law Lord at UK House of Lords

Lord Neuberger

Law Lord
UK House of Lords

9:30 - 10:00 UPC Update: The German Complaint and Brexit - Where Are We?

What happens to SPC’s if/when Britain leaves EU? Also protected by the European Patent Convention? Kevin Mooney returns to provide an update on the preparations for Brexit that the UPC have undertaken and will also address the ongoing complaint from Munich.
Kevin Mooney, Chairman of the Rules and Procedure Committee at UPC

Kevin Mooney

Chairman of the Rules and Procedure Committee
UPC

·         When will the German Constitutional Complaint be decided and how?
·         Will the UK participate?
·         Do we still need a Unified Patent Court and a Unitary Patent?
·         Is there still the political will to make it happen?
Kevin Mooney, Chairman of the Rules and Procedure Committee at UPC

Kevin Mooney

Chairman of the Rules and Procedure Committee
UPC

Dr. Matthias Zigann, Presiding Judge at Regional Court Munich I

Dr. Matthias Zigann

Presiding Judge
Regional Court Munich I

10:30 - 11:00 Injunctions in Germany - Really Automatic?

Public belief has it that German courts generally and “automatically” grant injunctions if they find a patent infringed. The presentation will outline the current situation and discuss possible changes to the law and court practice in view to industry concerns in cases involving live saving or complex products.
·         Exceptions to the “automatic” grant of injunctive relief in preliminary and main proceedings
·         Anti-trust and mandatory license defense in the life-sciences
·         Preliminary enforceability
·         Shortfalls of the enforcement procedure
·         The injunction gap
·         Possible changes to the law and court practice
Dr. Matthias Zigann, Presiding Judge at Regional Court Munich I

Dr. Matthias Zigann

Presiding Judge
Regional Court Munich I

11:00 - 11:30 Morning Break and Networking

11:30 - 12:00 Patients, Patents and Price: Can Life Science Innovation Survive the Politics of Affordable Health?

The incentive system in life sciences faces an existential challenge which could fundamentally change the way our businesses patent, publish, and innovate.  The political pressure to lower costs of patient care and curb perceived abuses of the patent system have led to numerous calls to curtail patents, term extensions, and other protections – but, can we change the course of the discussion through positive action?  This presentation will examine those challenges, propose steps we can take to demonstrate patient value, and invite discussion about how we can continue to deliver on our commitment to improving the lives of patients.
 
This session will:
·         Provide a summary review of (proposed) legislative changes to US / EU pharmaceutical patent law;
·         Examine voluntary steps companies can take to demonstrate commitment to core innovation and patient value;
·         Encourage discussion and best practice sharing among participants.
Aaron Smethurst, Director, Intellectual Property Policy at UCB

Aaron Smethurst

Director, Intellectual Property Policy
UCB

12:00 - 12:30 Legal Risk Mitigation & Minimisation Across Your Business

Issues across the business are inevitable, from the inadvertent disclosure of sensitive information through to adverse event reporting, patient interactions, manufacturing problems or product recall.  Whilst some risks can be avoided, it is often the inappropriate handling of situations and panic responses made by a business that can cause the greatest damage. 
 
Steps can be taken as a matter of good business practice to prevent or minimise business risk and exposure. With twelve years in house experience supporting business teams and functions within the pharmaceutical industry, Michelle talks through her insights and the practical steps she deems most effective.
 
The session will:
·         Give practical examples of risk exposure;
·         Cover steps that can be taken to more effectively handle issues when they arise; and
·         Cover steps that can be taken to better prepare teams and prevent or minimise exposure.
Michelle Davies, Legal Director at HGF Limited

Michelle Davies

Legal Director
HGF Limited

12:30 - 13:00 The EC’s Incentive Review – An Antibacterial SME's Perspective

The presentation will contain a summary of the proposed changes from the EU Review of pharmaceutical incentives and their possible impacts on small (and medium) size pharmaceutical companies and an example where the current European and US incentives are not successful (Superbugs vs new antibacterials/antibiotics)
·         The value of IP for SMEs
·         SMEs and the consequences of changes on them are often forgotten by legislators
·         An overview of why the current incentives are not successful at bringing “life-saving” new antibacterials to market, what has been tried and what is being proposed and their possible effects on IP community.
Stephane Hauduc, Discovery Chemistry and Intellectual Property Manager at Destiny Pharma

Stephane Hauduc

Discovery Chemistry and Intellectual Property Manager
Destiny Pharma

13:00 - 14:00 Networking Lunch

14:00 - 14:30 Patent Data Analysis

• What is the main usage of patent data analysis?
• How can data analysis strengthen your patents?
• What is the measurable ROI of such software?
What alternative forms of protection to patent protection exist for the pharmaceutical industry: Can gene sequences be protected by copyright? Developments in the drug names? Design Right in chemical structures?
·         Trade secrets
·         Trademarks – GSK’s Seretide inhaler.
·         Copyright
·         Designs – claiming infringement for the copy of medicine designs
Professor Mark Engelman QC, Head of Intellectual Property, Barrister at Hardwicke Chambers

Professor Mark Engelman QC

Head of Intellectual Property, Barrister
Hardwicke Chambers

Dr Guido Pontremoli, Corporate IP Patent Director at Chiesi

Dr Guido Pontremoli

Corporate IP Patent Director
Chiesi

Martyn Fish, Partner at HGF Limited

Martyn Fish

Partner
HGF Limited

15:30 - 16:00 Afternoon Break and Networking

That patent practice differs between Animal Health and Human Pharma may seem obvious, but a closer look at the differences reveals some interesting learnings.   For example, differences in regulatory requirements; infringement proceedings; product presentations; and even the strategy employed for patent prosecution can have implications for a Company’s Intellectual Property.
 
The presentation will provide examples of differences from each of these categories as well as illustrate real-world consequences to a patent estate. This will take the form of a comparison between Animal Health and Human Pharma patenting, wherein the following will be discussed:
·         Regulatory Pathways for Product Approval
·         Differences in Patent Strategies
·         Consequences for Patent Infringement Proceedings
Dr. Judy Jarecki-Black, Head, Patent Prosecution and Patent Litigation, Animal Health at Boehringer Ingelheim Animal Health

Dr. Judy Jarecki-Black

Head, Patent Prosecution and Patent Litigation, Animal Health
Boehringer Ingelheim Animal Health

16:30 - 17:00 Closing Keynote: AI and the Shifting Life Science Landscape

Data generation is accelerating daily. Combined with AI, robotics and IoT, this undoubtedly is driving disruption in the life science and healthcare landscape. As such, this unique quartet is enabling the sectors to build new business models for the future, revolutionising how medical treatments and other products are discovered, developed, produced, delivered and communicated to their end-users globally. In this unique talk from CEO of COGNEDT, Rahela, attendees will explore:
·         Why the life sciences industry is ripe for digital transformation
·         The inherent challenges and opportunities of AI, robotics, IoT  and data
·         What these changes will mean for lawmakers, standards organisations, law firms and in-house counsels

17:00 - 20:00 Chairman's Closing Thoughts and Evening Drink Reception